The effects of acidosis and hypothermia on blood transfusion requirements following factor VII administration

Anaesthesia and Intensive Care

Volumn 35, Issue 4, 2007, Pages 494-497

  Hall, K ^a   Forrest, P ^a   Sawyer, C ^a  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

Acidosis; Factor VII; Hypothermia; Surgery; Transfusion

Indexed keywords

ACETYLSALICYLIC ACID; ADRENALIN; APROTININ; CLOPIDOGREL; RECOMBINANT BLOOD CLOTTING FACTOR 7A; TRANEXAMIC ACID; WARFARIN;

ADULT; ANAPHYLAXIS; ARTICLE; BLEEDING; BLOOD TRANSFUSION; BODY TEMPERATURE; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG EFFICACY; ERYTHEMA; ERYTHROCYTE TRANSFUSION; HUMAN; HYPOTHERMIA; INTRAOPERATIVE PERIOD; MEDICAL RECORD REVIEW; MEDICAL RESEARCH; METABOLIC ACIDOSIS; MULTIPLE REGRESSION; PEROPERATIVE COMPLICATION; PH; POSTOPERATIVE PERIOD; POSTOPERATIVE THROMBOSIS; REPEATED DRUG DOSE; SIDE EFFECT; SURGICAL PATIENT; SYSTOLIC BLOOD PRESSURE; SYSTOLIC DYSFUNCTION; VASCULAR DISEASE;

EID: 34548286884     PISSN: 0310057X     EISSN: None     Source Type: Journal    
DOI: 10.1177/0310057x0703500405     Document Type: Article

References (12)

1. Lynn M, Jeroukhimov I, Klein Y, Martinowitz U. Updates in the management of severe coagulopathy in trauma patients. Intensive Care Med 2002; 28 (Suppl 2):S241-S247.
2. Haas T, Innerhofer P, Kuhbacher G, Fries D. Successful reversal of deleterious coagulopathy by recombinant factor VIIa. Anesth Analg 2005; 100:54-58.
3. Meng ZH, Wolberg AS, Monroe DM 3rd, Hoffman M. The effect of temperature and pH on the activity of factor VIIa: implications for the efficacy of high-dose factor VIIa in hypothermic and acidotic patients. J Trauma 2003; 55:886-891.
4. Wegert W, Harder S, Bassus S, Kirchmaier C. Platelet-dependent thrombin generation assay for monitoring the efficacy of recombinant Factor VIIa. Platelets 2005; 16:45-50.
5. Carr ME Jr, Martin EJ, Kuhn JG, Ambrose H, Fern S, Bryant PC. Monitoring of hemostatic status in four patients being treated with recombinant factor VIIa. Clin Lab 2004; 50:529-538.
6. Ingerslev J, Christiansen K, Calatzis A, Holm M, Sabroe Ebbesen L. Management and monitoring of recombinant activated factor VII. Blood Coagul Fibrinolysis 2000; 11 (Suppl 1): S25-S30.
7. Dutton RP, Hess JR, Scalea TM. Recombinant factor VIIa for control of hemorrhage: early experience in critically ill trauma patients. J Clin Anesth 2003; 15:184-188.
8. Ghorashian S, Hunt BJ. "Off-license" use of recombinant activated factor VII. Blood Rev 2004; 18:245-259.
9. Welsby IJ, Monroe DM, Lawson JH, Hoffmann M. Recombinant activated factor VII and the anaesthetist. Anaesthesia 2005; 60:1203-1212.
10. Diprose P, Herbertson MJ, O'Shaughnessy D, Gill RS. Activated recombinant factor VII after cardiopulmonary bypass reduces allogeneic transfusion in complex non-coronary cardiac surgery: randomized double-blind placebo-controlled pilot study. Br J Anaesth 2005; 95:596-602.
11. Levi M, Peters M, Buller HR. Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: A systematic review. Crit Care Med 2005; 33:883-890.
12. NovoNordisk product literature. From http://www.fda.gov/MEDWATCH/SAFETY/ 2005/novose_pi_fa.pdf.